Antimicrobial resistance (AMR) is a risk to patient safety because it reduces the range of antimicrobials available to treat infections. It also increases morbidity and mortality associated with infections caused by multidrug-resistant organisms. AMR may limit future capacity to perform medical procedures such as organ transplantation, cancer chemotherapy, diabetes management and major surgery, because of a lack of effective antimicrobials.
The Australian Commission on Safety and Quality in Health Care established the Antimicrobial Use and Resistance in Australia (AURA) Surveillance System in 2014. This has enabled national coordination of data collection and analyses, and an enhanced understanding of antimicrobial use (AU) and AMR across Australia, including local and national patterns and trends over time.
Comprehensive, coordinated and effective surveillance of AMR and AU enables effective strategies to be developed to prevent and control AMR.
AURA 2019 is the third report of its type on AMR and AU in Australia. It includes data about organisms that have been determined to be a priority for Australia, the volume of AU, the appropriateness of antimicrobial prescribing, key emerging issues for AMR, and a comparison of Australia’s situation with other countries.
Australian Commission on Safety and Quality in Health Care 2019